(a).
| Antioxidants | NAFLD condition | Study type | Status/outcome | Trial number/reference |
|---|---|---|---|---|
| Alpha tocopherol plus ascorbic acid | Inflammation, fibrosis, insulin resistance | Phase 2 and 3 | Diet and physical exercise are effective in NAFLD children compared to antioxidant therapy |
NCT00655018
(Bugianesi et al., [136]) |
| Tocovid Suprabio 200 mg (tocotrienols/vitamin E) | Hepatic steatosis NAFLD | Phase 2 | NA | NCT04704063 |
| Omega 3 fatty acids | Fatty liver | Interventional (clinical trial) | NA | NCT04281121 |
| Omega-3 fatty acid (DHA EE) and vitamin E | NAFLD and NASH | Phase 2 | Undergoing | NCT04198805 |
| Metadoxine | NAFLD and prediabetes | Phase 4 | NA | NCT02051842 |
| Lovaza (omega-3-acid ethyl esters) | NAFLD | Phase 4 | NA | NCT00941642 |
| Hydroxytyrosol plus vitamin E | NAFLD | Phase 3 | NA | NCT02842567 |
| Vitamin E | Fatty liver | Phase 2 | No association with the reduction of bodyweight and improvement in insulin sensitivity. Intrahepatic TG reduced by 27% |
NCT01792115
(Podszun et al., [125]) |
| Vitamin E | NAFLD and NASH | Phase 2 | NA | NCT03669133 |
| Vitamin E | NAFLD and NASH | NA | NA | NCT02690792 |